Newsroom

Die SORMAS-App in der Anwendung.
News
The Covid-19 pandemic affects more and more countries worldwide. Since the virus causes no or only mild symptoms in many infected people, researchers assume that the number of unreported cases is high. In order to slow down the further spread of the virus, health authorities are focusing on consistent management of contact persons of confirmed cases of infection. For this purpose, the German Public Health Service (ÖGD) will be able to use a special version of the SORMAS disease control app in the future.
01.04.2020
Blutproben
News
After an infection with the coronavirus SARS-CoV-2, patients have antibodies against the pathogen in their blood. These are retained over a long period of time and are an indication for a past infection. It is assumed that patients who have recovered from the Covid-19 disease cannot be re-infected with SARS-CoV-2. To date, no data are available on whether there is an unrecognized Covid-19 immunity in the population beyond the SARS-CoV-2 infections recorded. The Helmholtz Centre for Infection Research (HZI) in Braunschweig is now coordinating a study to investigate this question. Anonymous sera from more than 100,000 donors will be analyzed in the population study. The blood will be regularly tested for antibodies against the Covid-19 pathogen. The study will provide a more accurate picture of immunity and pandemic development.
27.03.2020
Virusoberfläche
News
The new coronavirus SARS-CoV-2 has been identified as the pathogen behind the COVID-19 pandemic. The virus contains a main protease termed Mpro (or also termed 3CLpro), which is involved in the development of the virus’ replication complex. It consequently forms a part of the virus’ replication process and is an attractive drug target. A research group led by Prof. Rolf Hilgenfeld at Lübeck University and the German Center for Infection Research (DZIF) has now determined the protease’s crystal structure.
20.03.2020
Prof. Gérard Krause, Leiter der Abteilung für Epidemiologie am Helmholtz-Zentrum für Infektionsforschung.
News
Weltweit infizieren sich immer mehr Menschen mit dem neuartigen Coronavirus, betroffen sind mehr als 140 Länder (Stand 15.03.2020). Deshalb hat die Weltgesundheitsorganisation WHO inzwischen die Situation zur Pandemie erklärt. Wissenschaftlich gesehen bedeutet der Begriff Pandemie lediglich, dass sich ein neuer Erreger global verbreitet. Dies sagt noch nichts darüber aus, wie schwer die Erkrankung COVID-19 für die Mehrzahl der Infizierten verläuft.
16.03.2020
Spritze
News
The human immune system can recognize and eliminate not only germs but also cancer cells. This is why treatments with weakened germs can help the immune system in its fight against cancer. Researchers at the Max Planck Institute for Infection Biology in Berlin have genetically modified the tuberculosis vaccine BCG in a way that it stimulates the immune system more specifically. Consequently, the new vaccine VPM1002 offers much greater protection against tuberculosis. A spin-off company of the Helmholtz Centre for Infection Research (HZI) in Braunschweig has transferred the results from basic research to clinical application. A clinical study with patients suffering from cancer of the bladder has now shown that a therapy with VPM1002 could successfully prevent the recurrence of tumours in almost half of the patients who had not responded previously to the BCG therapy. The results could lead to the early approval of the drug for the treatment of cancer of the bladder so that as many patients as possible can profit from this quickly.
21.02.2020

HZI in the media

Dr. Rolf Müller, Managing Director of Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), were both named laureates of the

22.12.2025
|
Research Information

... ein Interview mit Josef Penninger geführt . Er ist wissenschaftlicher Geschäftsführer des Helmholtz-Zentrum für Infektionsforschung in ...

21.12.2025
|
T3N

Institut für RNA-basierte Infektionsforschung (HIRI), einem Standort des Braunschweiger Helmholtz-Zentrums für Infektionsforschung (HZI) in ...

19.12.2025
|
healthcare-in-europe.com

Biosyntheseweg aufzuklären. Das HIPS ist ein Standort des Helmholtz-Zentrums für Infektionsforschung (HZI) in Zusammenarbeit mit ...

18.12.2025
|
Bionity.COM

Finanzierungsmöglichkeiten fehlen.

 

Josef Penninger, wissenschaftlicher Geschäftsführer des Helmholtz-Zentrums für Infektionsforschung (HZI)

16.12.2025
|
MedMedia

Korte from the Technical University of Braunschweig and the Helmholtz Centre for Infection Research (HZI).

 

The research was carried out as

12.12.2025
|
The Hindu

... des Leibniz Lungenzentrums Borstel, des Helmholtz-Instituts für Pharmazeutische Forschung Saarland sowie weiterer wissenschaftlicher ...

12.12.2025
|
Bionity.COM

Einrichtungen des regionalen Forschungsökosystems – darunter das Helmholtz-Zentrum für Infektionsforschung (HZI), das Deutsche Zentrum für

12.12.2025
|
EUROPE SAYS

Korte of the Technical University of Braunschweig and the Helmholtz Centre for Infection Research (HZI). The findings emerged from the

12.12.2025
|
The New Indian Express

Universität Würzburg. Seit 2018: Postdoc am Helmholtz-Institut für RNA-basierte Infektionsforschung (HIRI), Entwicklung Bayes’scher ...

12.12.2025
|
BIOspektrum

Center Borstel - Leibniz Lung Center, the Helmholtz Institute for Pharmaceutical Research Saarland and other scientific institutions in

11.12.2025
|
Technology Networks

von Humboldt professor, head of department at the Helmholtz Centre for Infection Research, Braunschweig and full professor at the Hannover

10.12.2025
|
European Research Council

Register now for the HZI-Newsletter